8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Mar 24, 2026·SEC
Cardlytics, Inc.(CDLX)Earnings, Financials & Key Ratios
CDLX•NASDAQ
$4.26
Price updated Jul 7, 2026
SectorCommunication ServicesIndustryAdvertising & MarketingSub-IndustryPerformance and commerce marketing
AboutCardlytics, Inc. operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing. The company was incorporated in 2008 and is headquartered in Atlanta, Georgia.Show more
- Revenue$233M-16.2%
- EBITDA-$20M+88.2%
- Net Income-$103M+45.3%
- EPS (Diluted)-19.50+50.1%
- Gross Margin45.05%+3.7%
- EBITDA Margin-8.46%+86.0%
- Operating Margin-20.21%+71.2%
- Net Margin-44.36%+34.8%
- ROE-326.02%-76.3%
CDLX Price & Volume
Cardlytics, Inc. (CDLX) stock price & volume — 10-year historical chart
Loading chart...
Accelerating Revenue Contraction Threatens Corporate Solvency Profile
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity exhaustion and insolvency
Key Thesis Takeaways
- Cardlytics faces a precarious outlook as its core advertising network experiences a severe 44.6% revenue decline in 2026Q1, signaling potential structural obsolescence in its intermediary model.
- The company's inability to scale fixed costs, evidenced by a -24.1% operating margin, combined with a negative equity position of -$4.0M, creates significant insolvency risk.
- Investors should remain cautious as the firm struggles to maintain liquidity with only $35.7M in cash against $210.0M in total debt.
Verdict Logic
Negative: The company's rapid revenue decline of 44.6% and negative equity position of -$4.0M suggest an unsustainable operational trajectory that warrants extreme caution.
CDLX Growth Metrics
Cardlytics, Inc. (CDLX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years11.63%
5 Years4.53%
3 Years-7.89%
TTM-24.54%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM46.9%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM49.95%
Return on Capital
10 Years-49.91%
5 Years-39.81%
3 Years-37.82%
Last Year-20.9%
Peers Comparison
Key metrics vs top competitors for Cardlytics, Inc. (CDLX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.26 | $24.74M | -0.22 | -16.18% | -44.36% | -326.02% | — | |
| $9.20 | $379.99M | -48.42 | -11.71% | -2.17% | -1.42% | — | |
| $20.52 | $2.94B | 21.60 | 6.85% | 21.96% | 18.57% | — | |
| $10.39 | $1.25B | -31.47 | 15.24% | -6.68% | -21.96% | — | |
| $94.66 | $6.27B | 69.09 | 15.24% | 9.48% | 5.13% | — | |
| $10.34 | $1.74B | 44.96 | 11.75% | 7.91% | 4.43% | — |
Compare CDLX vs Peers
Cardlytics, Inc. (CDLX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CDLX SEC Filings & Documents
Cardlytics, Inc. (CDLX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CDLX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CDLX Frequently Asked Questions
Cardlytics, Inc. (CDLX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Cardlytics, Inc.'s revenue?
Cardlytics, Inc. (CDLX) reported $205.7M in revenue for fiscal year 2025. This represents a 165% increase from $77.6M in 2015.
How fast is Cardlytics, Inc. growing?
Cardlytics, Inc. (CDLX) saw revenue decline by 16.2% over the past year.
Is CDLX profitable?
Cardlytics, Inc. (CDLX) reported a net loss of $94.7M for fiscal year 2025.
Dividend & Returns
What is CDLX's return on equity?
Cardlytics, Inc. (CDLX) has a return on equity (ROE) of -326.0%. Negative ROE indicates the company is unprofitable.
What is Cardlytics, Inc.'s free cash flow?
Cardlytics, Inc. (CDLX) generated $1.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.